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Interviews were conducted to establish a baseline for how orphan drug forecasting is currently
undertaken by financial market and industry analysts with the intention of understanding the
variables typically accounted for in such a model. A literature search formed the basis of
subsequent interviews conducted with experts from industry, payers, providers, legislators,
patient groups, and the FDA. Discussion then focused on elements of the market which are
poised to change in the short-term, how such changes might be reflected in existing models,
and/or how these models may instead need to be modified to adapt to the new environment.
We hypothesized that impending changes in the healthcare sector would indeed impact the
legitimacy of current forecasting models, and that significant changes would need to be
introduced to account for these new market forces. Our hypothesis, however, was not
confirmed, in that although much of the literature and, indeed, public outcry over rising
healthcare costs in general and drug prices in particular make a strong case for implementing
changes in the orphan market via payers, government, or other actors, an assessment of
healthcare experts regarding market changes over the next five years revealed a general
consensus that meaningful change will likely not occur during this timeframe for orphan
products, with the exception of a possible increase in pharmacoeconomic requirements for
drugs which are only marginally effective. Thus, current orphan drug forecasting models
constructed for use by financial and industry analysts correctly avoid discounting for these
potential changes, as they will likely not face significant changes in the US until closer to a ten
year time horizon. Potential exceptions to this conclusion depend on implementation and
regulatory treatment of the fields of personalized medicine and gene therapy, as developments
in these areas may closely interact with existing orphan drug legislation. Our results have
significant implications for all companies and stakeholders entering or currently operating in the
orphan market, and open the door for further quantitative and qualitative analysis.
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Chapter 1: Introduction
Orphan drugs occupy a unique niche in many pharmaceutical and biotech portfolios, and
maintain a perceived value proposition which is disproportionately high when compared with
other innovative products. The reasons for this perception relate primarily to increased revenue
driven by very high margins and market exclusivity, and by the public relations boon of helping
an underserved population of patients. The revenue benefits enjoyed by the industry stem
directly from the Orphan Drug Act, which, passed in 1983, created a wide range of incentives to
encourage drugmakers to dabble in a market for diseases which would not otherwise justify
such an investment.
However, in recent years, there has been call for reform across the healthcare landscape, and
nowhere are the cries as intense as in the orphan world, where emotion plays almost as
significant a role as other market factors. Patients, along with providers and advocacy groups,
clamor for newer, better, innovative treatments for more diseases, while payers attempt to
manage costs and to pay only for more efficacious treatments. This emphasis on
"pharmacoeconomics" is gradually growing in a number of forms across the world, as both
government and commercial payers begin to account for ever-rising costs in a macroeconomic
downturn. On top of these concerns lie the regulatory and legislative bodies on whose decisions
ultimately turn approval, access, and reimbursement to orphan drugs, and which, at least in the
legislative case, can be motivated at times by public opinion to capricious change, causing
stakeholders no shortage of uncertainty and concern.
Based on these observations, we hypothesized that the industry is poised to change in the short
term, whether due to a shift in the primary value proposition or on account of a legislative /
regulatory amendment, and that current models used to predict orphan drug revenues and
costs would thus need to be amended in the near future to account for the impact such changes
will inevitably have on existing pricing, reimbursement, and incentive schemes.
The primary purpose of this thesis is to examine whether the current incentive structure for
orphan drugs is likely to persist unchanged given upcoming developments in healthcare policy
reform, pharmacoeconomic demands, and the more general emphasis on cost containment. We
further endeavor to empirically consider what specific effects such changes might have on
revenues, costs, and incentives in the orphan product space, using industry and financial
forecasting models as a guide to the way these elements are currently represented. As the
thesis evolved, it became apparent that any attempt to categorize the short-term future of the
orphan drug space would be woefully incomplete were it not to include an analysis of the roles
of individual stakeholders in defining this future. As such, we ultimately suggest the unfolding
role each set of stakeholders must accept in emerging industry dynamics in order to collaborate
in developing a more sustainable value proposition in years to come.
This thesis is organized in the following manner. We begin with a comprehensive look at the
background and history of orphan drugs, considering, among other things, the legislative history
and implications of proposed changes to the Orphan Drug Act over the years. We next turn to
more recent times, examining successes and challenges encountered in succeeding years by
both companies and other industry stakeholders, and we survey cost containment measures
undertaken by foreign governments to try to reign in rising healthcare expenditures. Having thus
gained a more significant understanding of the primary factors affecting the current market for
orphan products, we discuss in detail the methods used for evaluating our hypothesis, before
launching into a comprehensive analysis of our results. We subsequently consider implications
and limitations of our work, thereby laying the groundwork for future studies, and we then
briefly discuss the likely impact of several additional challenges facing the industry. We conclude
with a summation of the lessons garnered through this analysis, and describe some of the
challenges individual stakeholders involved in orphan drugs will inevitably face in the coming
years, as the industry inexorably continues to evolve.
Chapter 2: Background
Orphan Drug Act of 1983
In the early 1900s, new treatments for many diseases were being developed at federally
operated labs and by non-profit organizations. By the early 1960s, however, the landscape had
shifted in favor of private, for-profit pharmaceutical companies providing most new chemical
entities and virtually all approved drugs, while federal and academic institutions focused more
on basic research and clinical studies 40. This system worked very well for diseases affecting large
groups of patients, as the high costs associated with bringing a drug to market could be offset by
addressing a large market size (whether with greater or lesser efficacy). However, patients with
rare diseases were often simply out of luck in looking for treatment, as pharmaceutical
companies had little incentive to develop drugs for these small markets. Consequently, in the
decade leading up to the orphan drug legislation passed in 1983, only 10 products which
qualified as orphan indications reached the market28 . Even molecules which had already been
discovered and may have been efficacious for treatment of a rare disorder were left on the shelf
or "orphaned", lacking a sponsor to conduct the research necessary for gaining FDA marketing
approval. Making matters worse, many of these products were unpatentable , further
exacerbating the dearth of development in this area. Spurred by the pleas of patient advocacy
groups, Congress unanimously enacted the Orphan Drug Act (ODA) in 1983 to provide economic
incentives toward the research and development of drugs for rare diseases. As Congressman
Henry Waxman (D-CA) eloquently put it, "They are like children who have no parents, and they
require special effort."
The original legislation attempted to provide incentives while reigning in the possibility of abuse
of the system for corporate profit. The primary incentives included a 7 year market exclusivity
period and a 50% tax credit for drug research costs. However, the legislation also specified that
a "rare disease or condition" which qualified for orphan designation be tied directly to the lack
of large economic potential. This ambiguity discouraged pharmaceutical makers from taking full
advantage of the incentives and in the first year of the program (1983-1984), the FDA received
only 15 requests for orphan designations. Congress thus amended the legislation in 1984 to
redefine rare diseases as those illnesses which affect fewer than 200,000 people in the US or for
which there is "no reasonable expectation of recovering development costs through US sales."
At that time, Congress noted the potential for abuse of the system, namely using the monopoly
status granted by market exclusivity combined with very high monopolistic pricing to create
blockbuster drugs on the back of taxpayer incentives, but ultimately decided that this was a
necessary risk to help induce industry participation40 . The ODA has subsequently been subjected
to multiple modifications, some larger than others, which have contributed heavily to the state
of the industry today. In 1985 the legislation was amended to allow market exclusivity for
patentable products as well and allowed for federal grants for clinical evaluation of orphan-
designated drugs. A 1988 amendment required a sponsor to apply for orphan designation
before submitting an application for marketing approval. In 1992 the FDA clarified the regulation
(especially with regard to what constitutes a violation of marketing exclusivity), by publishing
the Orphan Drug Final Regulations 2. In 1997, as part of the FDA Modernization Act, orphan drugs
were exempted from paying new drug application fees (a fee which is now over $1M). The Rare
Disease Acts in 2002 ensured that sufficient budget existed for the Office of Rare Diseases and
increased funding for the FDA Orphan Products Research Grant Program.
Just as important, perhaps, as the changes which have occurred in the legislation over the last
30 years are the changes which have not occurred. Spurred by popular sentiment, proposed
amendments to the act in 1990, 1994, and 2000 have taken on the concept of market exclusivity
and "excessive profitability", offering changes such as removing market exclusivity when patient
population exceeds 200,000 (as occurred with early drugs for AIDS such as AZT), creating an
"orphan drug windfall tax" which would tax all revenue earned on an orphan product beyond
twice the development cost plus 25%, creating a "sales trigger" which would allow competition
into the market just two years after approval if sales exceed $200 million, and reducing market
exclusivity to four years, with the following three years contingent on demonstrating "limited
commercial potential". Pharmaceutical companies protested vehemently in each case, arguing
that any reduction in the power of the available incentives would strongly decrease orphan drug
R&D and detract from the original purpose of the bill, thereby harming patients. Indeed, during
the time when Congress was debating these amendments, designation requests for orphan
products dropped significantly49. While the amendments ultimately failed to become law in each
instance, the repeated and determined nature of the attempts to reform the law (in the case of
the 1990 amendment, the changes actually passed through Congress only to be vetoed by
President Bush) would seem to indicate that given enough public pressure and willpower in
Congress, changes may one day indeed occur.
Figure 1: Orphan Drug Act key benefits overview and legislative history
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Industry Response to the New Legislation
The industry response to orphan drug incentives in the US has been impressive to say the least.
Dr. Tim Cote, head of the Office of Orphan Product Development (OOPD) at the FDA contends
that, "there is no question that the Orphan Drug Act is without a doubt the single most
successful piece of legislation that has ever been passed in human experience." Since the Act's
inception in 1983, there have been over 2200 requests for orphan designation in the US with
over 360 drugs reaching marketing approval, resulting in treatments for approximately 200 rare
diseases (as of the end of 2010)34. Additionally, the entire biologics industry effectively grew up
out of treating orphan indications, creating tremendous economic growth along the way. As of
2007, biologics comprised approximately 64% of the US orphan drug market, and new orphan
drugs / indications made up 2/3 of all biologic approvals in 2008-2009134. As an added benefit,
many research initiatives which originally took aim at orphan indications have spun into some of
the most successful treatments of all time. Statins, for example, which generated roughly $25Bn
in revenue in 2009, actually got their start based on research meant to address an orphan
condition known as homozygous familial hypercholesterolemias2 . Many countries have
implemented reform in the orphan space since that time, attempting to emulate the US success
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in spurring innovation. Japan enacted its law in 1993, Australia adopted similar legislation in
1997, and the EU followed suit in 2000.
Industry has found financial success with orphan products as well. In 2008, of 82 bestselling
orphan drugs from the top 50 companies, nine had sales of over $1bn and 14 over $500M.
Regarding the drugs themselves, more than 50% had sales of over $200M, with an average level
of $470M 28. Individual companies have also grown and thrived on the legislation. Genzyme,
started in 1981, focuses on disease areas including oncology and enzyme replacement
therapies, two of the largest orphan drug categories. Its first FDA orphan drug approval came for
Ceredase, used to treat Gaucher's Disease, and coupled with high price tags for many therapies,
(Cerezyme has an average sales price of upwards of $200,000 per year 28) it has ultimately built
its portfolio into revenues of $4.5Bn in 2009, leading to a buy-out by Sanofi Aventis in 2011 for
over $20Bn. This success considerably exceeded analysts' predictions as turning formerly fatal
diseases into chronic conditions served to increase the number of patients above previously
recorded prevalence levels. Other successful companies have followed suit, including Shire,
Celgene, Biomarin, and Actelion. Many of the drugs which began life as orphan products have
subsequently become blockbusters through off-label use or expansion to other indications.
Botox, marketed by Allergan, was originally approved for dystonia (a neurological disorder
affecting movement), which qualified it for orphan status. It has since become one of the
company's biggest revenue streams (over $1.3Bn in sales in 2009), due almost entirely to its use
for cosmetic purposes. Gleevec, which was unanimously approved as a treatment for chronic
myeloid leukemia in a record-breaking 2.5 months due to its tremendous treatment efficacy, has
since been approved for at least 8 additional indications, and produced almost $1.3Bn in US
sales in 2010. As of 2009, of 18 blockbuster drugs approved only in orphan indications, all but 4
were approved for multiple indications or involved significant off-label uses2
Rising Stakeholder Concerns
Yet it is a combination of this very success and several other unintended and more deleterious
consequences of the orphan drug legislation which has catalyzed public opinion, occasionally
riled Congress, and caused other industry stakeholders such as payers, physicians, and patient
advocacy groups to ponder mechanisms for fighting back against rising costs. It is commonly
understood that US healthcare expenditures have been rising rapidly in recent years. In 2009,
national health expenditures famously accounted for 17.6% of US gross domestic product,
averaging over $8,000 per capita. Of this expenditure, retail prescription drugs accounted for
roughly $250Bn, or over 5% of total national health spending, and this number is rising as well2 .
Specialty drugs, including those with orphan status, represent an even more rapidly expanding
cost, with a growth rate of almost 20% in 201033. These rising expenses, set against a backdrop
of depressed macroeconomic factors, have caused the high price tags of many specialty and
orphan drugs to become a source of particularly vehement popular ire. The public argues that
taxpayers are subsidizing corporate success and greed (although in fairness, blockbusters in the
orphan space are still relatively rare 28) through the orphan drug program incentives, while
patients suffering out of pocket expenses (a typical coinsurance plan can require a patient to
stake 20% of the cost of a drug) feel that even if much of the profit is plowed back into R&D,
they are being asked to carry an unfair load of the research funding for other diseases. As one
industry leader contended, "From a patient perspective, they don't appreciate that Genzyme
was built on their backs." A Kaiser public opinion poll in 2008 found that 79% of those polled felt
that the cost of prescription drugs was unreasonable, and an identical 79% cited the quest for
high profits on the part of drug companies as bearing primary responsibility for those prices2.
Physicians and patient advocacy groups such as the National Organization for Rare Diseases
(NORD) are concerned about rising costs if they lead to decreased patient access to drugs, but
they are equally concerned about pushing back too hard on industry and decreasing the
innovation levels which have dramatically improved the lives of countless patients since the
legislation went into effect. Payers have historically been generally unconcerned with rising
prices on orphan drugs because they made up such a small part of the overall drug pie (roughly
5% in 200928). However, the rise in initial prices from manufacturers, coupled with a feared
barrage of orphan products coming through pharma pipelines to treat rare oncology conditions,
now has fully captured payers' attention. Orphan designations increased at a CAGR of 17.7%
between 2002 and 2008 28. A 2006 meeting of the Academy of Managed Care Pharmacy listed
the rising cost of orphan drugs as one of the industry's primary concerns for coming years 9 .This
fear is coupled with a perceived impending wide-spread adoption of biomarkers and
personalized medicine, which could in theory serve to create unique drug cocktails for every
individual. Would each of these cocktails thus be considered an orphan product? The
government has also expressed concern with the rising costs of pharmaceuticals, while
continuing to recognize the importance of encouraging industry involvement in orphan product
development. On July 24, 2008, in testimony before the Senate Joint Economic Committee,
Madeline Carpinelli of the PRIME Institute presented findings showing extraordinary price
increases of 100% or more in the pharmaceutical market (some as high as 3000%), and noted
cases of orphan drugs which have typically "flown below the radar" demonstrating
unwarranted price increases as well 4. This testimony generated a slew of Congressional
backlash. As Senator Amy Klobuchar (D-Minn.) fumed, "Something's going on, and I don't think
it's the law of supply and demand. This seems to be simple price gouging to me."" A
Government Accountability Office report released in February 2011 further emphasized the
government's concern over drug price increases eclipsing other medical expenses49 . With the
expansion of Medicaid coverage brought about by healthcare reform, government sources are
looking with increasing skepticism at prices for specialty products and may now consider actions
previously thought to be anathema in the US healthcare system in order to effectively curb such
costs.
In addition to stakeholder concerns, several characteristics of the Orphan Drug Act lead to
ethical situations which may result in pushback or a call for change. In June 2009, Genzyme was
forced to close its plant in Allston, Massachusetts, when viral contamination was discovered. In
November 2009, the FDA found foreign particles consisting of steel fragments, non-latex rubber,
and fiber-like material in vials of Cerezyme and Fabrazyme, further distressing supply. Orphan
drug laws protecting marketing exclusivity had discouraged other drug makers from pursuing
treatments for diseases like Fabry, and the result has been a shortage such that many patients
only have access to a third of the drug supply they would normally receive, prompting multiple
24lawsuits and attempts to break the drug's patent protection . More generally, the marketing
exclusivity clause often leads to a "race to market approval", leading multiple companies to
pursue research into a treatment which only one can end up marketing, and thus potentially
diverting funds from other patients in need while also driving up prices. In 1999, IVAX and BMS
raced to get a drug approved for Kaposi's sarcoma, a rare virally-caused tumor, with IVAX
making a less-costly generic version of the same drug. BMS beat IVAX out in applying for
marketing approval by 6 days, resulting in the drug Taxol (paclitaxel), which garnered over
$1.5Bn in sales in 2000. Additionally, despite healthcare reform removing lifetime caps on
insurance plans, and although many companies offer patient assistance programs to help those
unable to afford out of pocket costs, many of those patients who are deemed "able to pay" face
serious financial difficulties, and still others do not get the assistance they need. A Kaiser study
in 2009 found multiple examples of patients who ran up very significant bills for cancer
treatment and were in danger of losing access to necessary drugs. Finally, as orphan drugs need
not be novel new compounds, industry has at times found ways to gain approval and an orphan
designation for existing treatments, causing an extreme price bump and widespread
condemnation from the public and the media. Examples of this methodology include
Oxandralone, an AIDS drug in the 1990s, as well as Colcrys, Achtar Gel, and most recently, a drug
called Makena used to treat the risk of pre-term labor. Makena, marketed by KV Pharmaceutical
Co, was previously made by compounding pharmacies as 17P (hydroxyprogesterone) and was
used off-label for years for the same indication. By virtue of its approval and orphan designation,
the drug price spiked from between $5 and $15 per shot to $1500 per injection, resulting in total
costs per patient of up to $30,0006. Indeed, Senator Amy Klobuchar, the same senator who
responded vehemently to the 2008 testimony from the PRIME institute on drug price increases,
has sent a letter to the FTC calling for a probe into egregious pricing of Makena51. The FDA
responded in an unprecedented letter informing compounding pharmacies that it will not take
enforcement action against them if they continue to make the drug, in direct contradiction to a
letter sent earlier by KV9.The company subsequently responded by slashing the price more than
50%, although it remains unclear whether this move will pacify the intense patient, provider,
and political outcry46.
Industry Reactions
Industry passionately rejects these criticisms and contends that while there are at times cases
where blockbuster drugs are created from orphan beginnings, these cases are rare and are
offset by the extraordinary risk taken in developing treatments for extremely small patient
populations. Additionally, as Dr. Cote points out, "A lot of orphan products are downright cures.
It makes us all feel really good to be able to make a downright cure. That is a rare thing in
medicine." As such, few people complain about the cost of drugs like Gleevec, which has a 5
year survival rate among CML patients of roughly 90%-95% [data from Gleevec website].
Secondly, expansion to other indications remains one of the primary reasons companies are
willing to dabble in such a risky market in the first place. A Datamonitor report in 2009 estimates
that, "The sales achieved from a single orphan indication alone can offer little incentive for a
manufacturer given the small market size. The real monetary gains are achieved through
expanding the number of indications of an orphan drug once at market either through targeting
multiple indications... or by expanding into other orphan indications with larger patient
populations." Similarly, Mark Fishman, President of Novartis Institute for Biomedical Research,
pointed out, "If we understand the mechanism in a narrow or niche indication then of course we
hopefully will be able to extend it out to other diseases which share underlying mechanisms." 28
By this measure, companies argue that pricing drugs at a higher rate for niche indications is the
only way to recoup the massive costs which go into R&D and clinical trials for every drug
candidate, especially taking into account the large risk of failure. Even drugs which were
reformulated for orphan indications out of generic substances have undergone extensive safety,
efficacy, and dose determination trials, as well as FDA approval and marketing, at significant
expense to the drug's sponsor, for which they deserve to be reimbursed.
One other trend within industry deserves to be noted here as well. Historically, large
pharmaceutical companies have always had a hand in the orphan market, and many continue to
do so. However, the traditional pharma model does not necessarily lend itself easily to this
market. For one thing, pharma has traditionally excelled at maintaining and incentivizing
extensive sales forces designed to carry out large-scale marketing campaigns for new and
existing products. This methodology places the focus squarely on physician contact over patient
interaction. Orphan indications, by their nature, require intensive company - patient interaction,
whether through assistance programs, education, or support for all aspects of disease
management. Success is measured by acquiring and retaining individual patients, not geographic
segments of physicians. In orphan drugs, "the heart and soul of the commercial [effort] is the
patient community. Big Pharma needs to transform the commercial model, and that is no small
undertaking," says Jerry Cacciotti, VP at IMS Health 28. Additionally, limited understanding of the
market may hinder development efforts. Perhaps more importantly given the current economic
environment, large companies with billions in their pockets are easy targets for negative PR
which may result from the high pricing which typically accompanies orphan products. Although
this effect is somewhat offset by the positive publicity inherent in treating diseases with a large
unmet medical need, these factors cumulatively have historically held large pharmaceutical
companies back in their pursuit of new development opportunities.
Of late, however, big pharma has announced plans to get involved with orphan diseases in a
more substantial way. Sanofi Aventis purchased Genzyme this year for over $20Bn. GSK
launched a new unit in 2010 focused on R&D for rare diseases, following a licensing agreement
with Prosensa and a follow-up deal with JCR Pharmaceuticals Co, a Japanese maker of enzyme
replacement therapies. Pfizer has an active rare disease unit and purchased Protalix, an Israeli
company developing a plant cell based treatment for Gaucher's disease, in 2009, prompting
then-CEO Jeff Kindler to claim, "We would have never done that deal in the old Pfizer. We are
doing things today we would never have done a few years ago. Necessity is the mother of
invention."28 The rationale for this sudden influx into rare disease research is multifaceted. The
vast increase in approved products with pharmacogenomic labeling capitalizes on the promise
of personalized medicine and has demonstrated the unavoidably shrinking market size of
traditional indications, thereby making niche markets like orphan drugs less frightening by
comparison. As Jerry Cacciotti pointed out, "Drug makers are more interested in smaller
opportunities generally, and orphan drugs by their nature fall into that smaller market
opportunity." Additionally, by virtue of affecting smaller patient populations, orphan indications
traditionally entail lower clinical development costs, smaller trials (potentially even with the use
of surrogate endpoints and non-placebo controls), and expedited review by the FDA, in addition
to the incentives affiliated with the Orphan Drug Act discussed above. Safety profiles for orphan
drugs are also less relevant, as the benefit-risk ratio in cases where no other treatment exists,
combined with strong patient advocacy, almost always effects a scenario whereby non-life
threatening side effects fall by the wayside. All of these factors, however, pale in comparison to
the high margins that orphan drugs traditionally return. Pricing has historically been based on
"what the market will bear", which has resulted in the potential for significant earnings, even
based on lower sales in a smaller market. This pricing, though, as with traditional
pharmaceutical products, is coming under increasing pressure from multiple stakeholder angles,
as Jacqueline Kosekoff, CEO of United Healthcare subsidiary Prescriptions Solutions, succinctly
described it, "I suspect something is going to happen. Whether it is the orphan drugs that are
the straw that breaks the camel's back or whether it's the huge barrage of oncologic drugs that
are coming our way that is going to be the straw, I don't know. I just see it."28
Figure 2: Key trends driving large pharmaceutical companies toward orphan product
development
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Changing Paradigms
The confluence of factors driving up costs thus coincides with decreasing tolerance for such
costs in the current macroeconomic environment and has prompted a number of different
approaches to reigning in healthcare drug spending, which in turn may affect orphan drugs as
well. The first (and some would argue least likely to succeed) mechanism has been on the
legislative front. As mentioned above, legislation to shorten the exclusivity period, tax
Pexcessive" profitability, or at least claw-back tax subsid es for very successful drugs has
repeatedly been introduced in Congress only to ultimately fail. Bills were introduced in 2011
which take on drug prices more generally by attempting to shorten patent expiration on
biologics to seven years from twelve years and to allow importation of FDA approved therapies
from other countries. The former would seek to hasten generics coming to market, and the
latter, which has been facetiously dubbed "The Death of the Pharmaceutical Industry Act" by
some in the media, attempts to balance the higher prices paid in the US against those paid in
other countries. Neither measure stands a large chance of success, but the implications are
clear. Washington, reflecting popular sentiment, is not immune to external pressures and
desires to curb retail drug prices in any way possible. A second mechanism, embraced by some
payers, is to attempt to more carefully assess outcomes to determine efficacy of the care
provided. This pharmacoeconomic focus can come in several flavors. The simplest application is
to require a demonstration of clinical value through measurable outcome measures, thus
showing that a drug is actually effective in achieving its goals within a target population. More
drastically, a drug could be required to show cost-effectiveness from a point of view of valuing
human life. The UK's National Institute for Health and Clinical Excellence, for example, has
traditionally only approved therapies which are valued at less than £30,000 per Quality Adjusted
Life Year, effectively putting a dollar figure to the value of one year of life [NICE website].
However, in the US, the FDA may not make drug approval decisions based on cost, and payers
are limited in this type of direct cost control by medical need and patient advocacy. Another
potential mechanism for controlling costs has been to restrict use of specialty products, require
prior authorization, restrict any off-label use (even when recommended by a specialist), increase
the formulary tier on which a drug is available, and increase copayments and coinsurance for a
drug. The latter trend especially has been accelerating in recent years. Medicare recently began
requiring coinsurance for specialty products (i.e. Medicare part B pays typically pays only 80% of
the cost of specialty products with multiple indications), and as the figure below clearly
demonstrates (Figure 3), retail payers have followed suit, transferring more of the cost burden
to patients, industry (through patient assistance programs), and charitable organizations and
patient groups such as NORD. In fact, a Benefit Design Study by the Zitter Group in 2008 found
that 70% of insurers raised copayment or coinsurance rates in the twelve months leading up to
the study, and payers noted that they could typically transfer responsibility for more than $350
per month to the patient without seeing members forgo medically necessary care 9.
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Figure 3: Cost burden shift toward consumer payments for specialty products
Source: InVentiv Advance Insights, Somerset, NJ
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Where patients in these situations seek funding for drugs is yet another conflict area. Drug
makers have fought back of late through a program where many manufacturers are providing
coupons or vouchers which cover much of the out-of-pocket cost associated with a drug. For
example, Enbrel and Humira are anti-TNF biologic treatments used to treat inflammation in
autoimmune disorders such as rheumatoid arthritis and normally cost thousands of dollars each.
The manufacturers (Amgen and Abbott respectively) issue cards which reduce patients'
copayments to just $5-$10 per month, with the insurance company footing the rest of the cost
and making very limited use of the drug company's own resources. This tactic contrasts strongly
with the goal of patient assistance programs, in which the drugmaker instead foots the entire
bill16. How long this tactic can continue is another matter entirely. Drug companies are using the
coupon/voucher method to keep patients on branded drugs longer as well, and with major
statins such as Lipitor going off-patent in 2011, the issue is in payers' direct line of sight, even
irrespective of the specialty drug impactA.
Foreign Approaches to Cost Issues
One direction to examine regarding how to potentially deal with the array of pricing, access, and
reimbursement issues plaguing the specialty drug market is the way other governments have
tackled such problems. As several scholars have claimed (albeit with some caveats), "the US is
the only major industrialized country without regulated prescription drug prices."s2 What is clear
is that most other industrialized countries do indeed have controls in place to limit the system
costs of healthcare in general and prescription drugs in particular. How have other nations
managed to control these costs so effectively?
The European Union has a centralized orphan designation and approval process through COMP
(Committee on Orphan Medicinal Products) and EMA (European Medicines Agency). This
process is similar to the US in some ways (i.e. they share a designation request form), but
different in others (i.e. market exclusivity can be revoked for drugs which are "sufficiently
profitable", although this provision has never actually been invoked). Orphan diseases are
defined as those affecting fewer than five people in ten thousand, and orphan status confers 10-
year market exclusivity, direct access to a centralized procedure for EU market authorization, a
50% fee reduction for regulatory procedures, and free scientific advice". Although the laws
have been successful in Europe as well (720 orphan designations leading to roughly 60 products
by 2010) [European Medicines Agency Press Release, May 19, 2010], they have not seen quite
the same level of impact as in the US, largely due to a lack of harmony between member state
policies, although the EU is currently working to centralize even more of the processs 2. From a
pricing and reimbursement perspective, however, member states differ widely in their
approaches. In the UK, for example, as mentioned above, NICE may choose not to reimburse a
drug if it deems the overall cost-benefit for a treatment to be minimal. Although NICE may be
losing some of its power via a restructuring of the NHS, it still functions as a shield for payers to
restrict coverage, as evidenced by its recent refusal to approve Roche's drug, Avastin for use in
metastatic breast cancer, following another rejection for use in colorectal cancer last year. As
NICE chief executive Andrew Dillon remarked, "the evidence for the effectiveness of [Avastin] in
prolonging survival wasn't robust. Overall, [the drug] didn't show enough of a demonstrable
benefit for it to be considered a cost-effective use of National Health Service resources." 29 As
mentioned above, US law prohibits the FDA from making approval decisions based on cost, but
the FDA in this case revoked Avastin's use for breast cancer as well, citing efficacy concerns.
Other countries have similar rules in place to look at cost-effectiveness data, primarily affecting
reimbursement decisions, not coverage. Many countries in the EU, for instance, reference prices
in other member states in making decisions (i.e. Spain, France, Italy, etc). Several will look at
comparable treatments if they exist and try to determine whether a drug is truly "innovative",
and many will also try to limit coverage to only the most efficacious treatment in a class.
Germany maintains a group to independently determine clinical benefit (called IQWiG), and has
historically had more free pricing than the rest of the EU, but it recently restructured its system
such that drug makers must now negotiate prices with individual sick funds. Canada warns drug
makers that they must stay within "excessive" profit rates or risk limitation or prohibition on
sales. Japan also implements an orphan program similar to the US, with 10 year market
exclusivity, 6% tax credits and up to a 10% lower tax rate. However, Japan implements a sales
tax of 1% on revenues above )100M until the subsidies earned during development have been
repaid 48. These strategies have all worked to an extent to keep costs down. In 2008, prices for
drugs in the EU were on average 40% lower than prices in the US, with Italy and Germany at
55% and 70% of US drug prices respectively52. As evidenced by the recently introduced
legislation in Congress, this discrepancy rankles with US taxpayers. Thus the question we are left
to consider is whether the US will ultimately consider adopting any form of negotiated prices for
drugs in the future, and how would such a decision affect research, development, and marketing
of specialty and orphan products going forward?
Chapter 3: Thesis Objective and Methodology
Thesis Objective
Several sets of professionals rely heavily on being able to predict revenues from orphan drugs.
While the process of developing a drug is by definition extremely risky, both throughout the
clinical phases and certainly when dealing with the various regulatory bodies in the US and
abroad, it becomes even more difficult when considering the post-approval process which
includes getting the drug priced, reimbursed, and adopted by physicians and patients. Financial
analysts attempt to model these predictions in an effort to understand their effect on a
company's stock and value, for which one blockbuster drug's performance can be immensely
impactful. Drug companies similarly employ many individuals to help understand the post-
approval process, in the hope of effectively predicting revenues, devoting adequate resources,
allocating funds correctly, and understanding the competitive landscape and their brand image.
The objective of this thesis is to try to understand which factors contribute to these forecasting
models for orphan products, along with the sensitivities relevant to each, and to then examine
potential factors which may be changing in the healthcare landscape, with the goal of
understanding whether forecasting models as they currently stand in the US will remain
accurate through a five year time horizon, based on the assessments of experts from across the
various stakeholder perspectives in the healthcare space. Secondarily, we will also attempt to
examine the impact of the Orphan Drug Act through time, noting its successes and abuses and
considering any additional challenges which experts anticipate experiencing in the short term
future, with the goal of describing how stakeholders will need to adapt to any changing
paradigms going forward.
Review of Existing Literature
An extensive review of existing literature was performed in order to begin to address the
questions proposed and to better understand the historical context and current trends within
the orphan industry, with the ultimate goal of forming the basis for discussions with industry
and financial analysts as well as healthcare experts. This review encompassed scholarly articles
from the fields of science, medicine, business, ethics, law, and health policy, as well as
presentations and other publications put forth by regulatory bodies in the US and EU.
Additionally, many articles in the press, journals, and other media were used as an indication of
current and relevant developments in the orphan product space. Company websites were used
wherever possible to assess safety, efficacy, and sales data firsthand. The websites associated
with the various regulatory bodies (such as fda.gov, e-rare.eu) also functioned as a good source
to understand the challenges currently facing those bodies, along with recommendations for
how to further the cause of drug research in general and orphan diseases in particular. Patient
group sites such as NORD (www.rarediseases.org) and Orphanet (www.orpha.net) provided
corroboration for statistics related to specific orphan diseases and drugs, and consulting reports
were used whenever possible to help understand company strategies and trends in the orphan
market.
Interview Guides
To assess our hypothesis that existing models fail to consider changes currently occurring in the
healthcare system and to better understand the distinct elements of those changes, two
interview guides were created, one suited for understanding baseline forecasting models, and
the second for gathering the viewpoints of a wide array of healthcare experts. The forward-
looking aspects of each interview guide are based primarily on data unearthed through the
literature review process, and represent a fairly comprehensive view of the primary trends and
developments impacting the orphan space. All questions were phrased in a fairly open way,
representing the qualitative assessment each is meant to seek out. Additionally, each
interviewee was asked one very open-ended question about major changes to the orphan space
in the next five years, in an effort to allow the respondent to express his or her individual
feelings about the most majorly impactful trends on the overall orphan drug industry and
revenue forecasting process.
Forecasting Model Baseline Interview Guide:
1. Name/background/current position/experience with orphan products?
2. Can you describe the process of valuing a new orphan drug, including variables you
consider, as well as their sensitivities?
3. What are the primary differences in US and EU/International policy which may impact the
profitability of orphan products?
4. What are the key differences between forecasting orphan drugs and regular drugs?
5. Do you consider any potential upcoming legislative changes due to healthcare reform or
potential new pricing limitations or pharmacoeconomic conditions when forecasting drug
revenues?
6. How has the orphan market changed in the years since the law took effect (or since you
began covering companies which make orphan drugs)?
7. If Gleevec or Cerezyme were launching today, what would be done differently and how
might that change impact profitability?
8. What changes do you see in the orphan market in the next five years which may affect
profitability? Are any of these factors taken into account in existing forecasting models?
Healthcare Expert Interview Guide:
1. Name/background/current position/experience with orphan products and legislation?
2. Has the orphan drug legislation been successful in your view? Why or why not?
3. Have there been abuses of the system in any way?B
4. What is your opinion on blockbuster drugs which start in the orphan category and expand
from there into multiple indications (orphan or otherwise) or which maintain very high
pricing levels? i.e. Gleevec, Cerezyme, etc?
5. How do you think healthcare reform will impact orphan drug pricing? How will it impact
orphan drug incentives overall?
6. Do you believe the orphan product space is currently undergoing an increased emphasis
on pharmacoeconomics? How will this impact affect orphan drugs in the short/long term?
7. Will public outcry on drug prices and the determination to pursue cost containment in
healthcare prompt a reexamination of the Orphan Drug Act? How might it change? Do
you feel changes are warranted?
8. Do you think the FDA is employing a greater import on safety currently? Will the FDA
amend the safety constraints for orphan products (whether more tight or lax)?
9. Do you believe big pharma will continue to pursue orphan indications? What impact will
having more players in the orphan space have on the public view of orphan incentives?
10. Do you think there are any key differences in the market today over in the past (i.e. if
Gleevec or Cerezyme were launching today, what would be done differently and how
would that impact profitability)?
11. What other changes in the next five years do you see affecting the orphan market, from
the perspective of pricing, reimbursement, regulation, incentives, or costs? How about
longer term?
Selection of Interview Participants
Analyst interview participants were selected through several means. Financial analysts were
selected by combing through the investor Relations section of the websites of biotech and
pharmaceutical companies which produce orphan products and subsequently tracking down
contact information for several of these individuals and setting up a time to meet. This method
met with moderate though limited success, as many of these analysts were too busy to arrange
a meeting time in their schedule. Industry analysts on the forecasting side were recruited
through professional network contacts as well as through contacts of my professors and thesis
advisors, and these individuals were much more forthcoming in giving of their time and
information to this thesis effort. While this imbalance certainly represents a bias toward
industry forecasting mechanisms over those of the financial industry, our research and
subsequent interviews revealed that this bias is in fact warranted, given the much more robust
processes employed by industry in pursuit of accurate forecasts, as detailed below.
The healthcare expert pool ranged across a wide variety of stakeholder perspectives and
experience levels, and given time constraints, an optimization process was undertaken to
identify the most valuable candidates for interviews. These individuals were selected through a
combination of contacts from my professional network, thesis advisors, thesis sponsors, HST
professors, and leads drawn from preceding interviews. The result has been twenty-four
interviews with experts from across the healthcare field, including industry professionals,
commercial payers, government payers, providers, reimbursement experts, healthcare
consultants, regulatory staff members / consultants, legislators, and patient advocacy
professionals. These individuals represent a broad swath of the healthcare landscape, and their
opinions, while clearly not fully representative of the overall healthcare field, are sufficiently
informed to act as the basis of our limited pilot study and help answer our thesis questions.
It is worth emphasizing that the goal of these interviews was not to reach statistically significant
conclusions, but rather to synthesize the initial impressions of stakeholders from across the
healthcare landscape in light of the current market environment and to highlight any potential
changes which may affect the validity of existing forecasting models used by both the
pharmaceutical and financial industries.
The selection of survey participants was intended to serve as an unbiased evaluation of the
current state of thinking among those heavily involved in the healthcare space and to act as a
framework for a future study with more significant resources. It is acknowledged that such a
larger study may be necessary to justify both significant changes to existing models as well as
any public policy implications, but we believe that the opinions elicited in this pilot study yield a
reasonable perspective of what can be anticipated in the area of orphan drug development, and
may further be extrapolated to help understand policy and pricing developments in the field as
a whole.
The identities of all those interviewed is contained in an appendix to this document. However,
their individual responses and quotes will remain anonymous and confidential for the purposes
of this thesis.
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Chapter 4: Interviews and Results
Summary ofAnalyst Interviews
Out of a total of six analyst interviews conducted, two were performed with financial analysts at
two competing financial institutions in an effort to understand across the industry how the
process of orphan drug forecasting is typically performed. The resulting strategy is fairly passive,
in that they endeavor to receive guidance from pharmaceutical or biotech companies regarding
pricing and adoption rates for a drug, relying on the sponsor company alone to perform the
required sensitivity analysis and accurately discount the results. They can then estimate the
number of anticipated patients and arrive at revenues based on an assumed price per patient
per year, subject to the aforementioned adoption rates. A discount for competition is added as
well, although this discount is clearly less relevant for most orphan products. Second to that,
they will aim to corroborate this analysis using analogs if possible, although once again this
process is often less feasible when assessing a drug in the orphan space. Additionally, analysts
will discount the average sales price they are given by a factor of between 5% and 20%, to
account for patient assistance programs and a lower hospital formulary price. On top of these
discounts, they factor in some mandatory price cuts in the EU for government payers (often as
much as 10%), and thus arrive at a revenue number. Regarding changes in the next five years,
analysts interviewed believed that patient groups will become much better defined through
registries and increasing connectedness among various populations and this in turn may lead
payers to worry that with the advent of personalized medicine, ultimately every individual will
have their own "orphan" treatment cocktail, with similarly high pricing causing an unsustainable
rise in healthcare costs. However, the belief was that significant changes will not enter into the
orphan space until closer to a ten year time horizon, by which point the realities of orphan
treatment cocktails will push the government to interfere legislatively, and pharmacoeconomic
data will additionally catch up with orphan drugs and force a justification for proposed pricing.
The four industry analysts interviewed presented a very different picture for the forecasting
process, one which is much more robust and seems to feed into the information which financial
analysts are given. As one industry consultant pointed out, "Wall Street just basically reports
what they hear." The primary variables considered in the forecasting process described by
industry included the following:
* Understanding the drug's position in the treatment paradigm
* Competition, if it exists (including non-pharmaceutical approaches)
* Pipelines of other companies
" Epidemiology of the target condition
* Complementary or substitution-focused diagnostics which might amplify or decrease market
share
" Proprietary position of the drug
" Manufacturing challenges or challenges to the manufacturing supply chain
e Marketing capabilities and effect on market share
* Route of administration
" Prices of anything which can be viewed as an analog
" Sales channel (PCP, specialist, etc) and expertise / ease of marketing to that channel
e Patient flow (from initial treatment to second line to treatment holiday, etc)
* Patient advocacy strength (affects pricing flexibility as well as regulatory predictions)
e Impact on life expectancy, quality of life, etc
These models also consider a particular drug's niche to better understand the expected
adoption rate and resultant market share. This process asks questions such as: if a competing
product exists, are there issues with diagnosis, safety, efficacy, or selectivity, in order to
determine if a particular drug will grow the entire market, or merely snag some of a
competitor's existing market share. In looking at the way orphan drug forecasting differs from
regular drug forecasting, industry analysts pointed to the obvious dearth of competition in many
cases, but also identified some more unique characteristics. In particular, they recognized public
policy impact on speed of adoption due to high pricing as a concern which may contribute to the
discount factor applied, as well as the difficulty associated with accurate predictions of both
patient numbers and weight (for weight-based dosing). IMS, a primary source of drug data for
industry, often does not cover smaller, orphan disease populations, and even physicians and
specialists are often either inaccurate or simply misinformed in their estimates of total number
of patients, forming selective biases based on geography, the condition of patients physically
able to come see a physician, and the fact that affected populations may be shifting as well (i.e.
the "baby boomer" generation reaching retirement age in the US beginning in 2011). Pricing is
further tuned by testing proposed value with payers to understand formulary restrictions and
testing with physicians to understand prescription practices, especially if a copayment or
coinsurance is likely to be involved. Revenues are then discounted for any increased regulatory
risk associated with statistically lacking trials or surrogate endpoints used, to ultimately arrive at
several bounded scenarios for pricing and adoption which lead to effective revenue estimates.
The process ex-US is similar, and most analysts do not break out country-specific numbers
(unless the target population is geographically concentrated), but all amend pricing for
government negotiations and incorporate a discount factor representing the potential for
restriction based on QALY analysis in countries such as the UK. Additionally, convenience seems
to garner a much lower pricing premium in EU countries focused on clinical value, so pricing
theory is instead focused on benefits of reduced hospitalizations, complications, and mortality.
What these detailed models do not seem to include, however, is a map of additional indications
which might be pursued (as this can present serious regulatory issues) or significant off-label use
which may greatly bolster sales (one analyst noted that Provigil, Cephalon's analeptic drug, has
wide-spread off-label use, accounting for an estimated 80% of its $1.1Bn in 2010 sales), as well
as discounting associated with scenarios such as a change to US law to emphasize
pharmacoeconomics or changes implemented by specific payers which amend the rules for
copayments and formulary restrictions in the years beyond launch. Changes to stipulations of
the Orphan Drug Act could also redefine the orphan space and change the patent and marketing
protection for a product as discussed above. Although it is unrealistic to attempt to predict the
future in a revenue model, scenarios demonstrating the lower bound of revenue projections
could reasonably be expected to include any impending changes to these very significant market
factors as a discount factor to overall revenues, allowing the company to create contingency
plans should these changes, in fact, occur.
When asked if they believed that any similar changes may be imminent in the short term (up to
five years out), analysts expressed several perspectives. One respondent predicted that pricing
pressures would continue to mount across the medical landscape, and with those rising
pressures will come public outcry over drug prices, but ultimately no action on orphan
medications, as patients and patient advocacy groups will continue to clamor for next-
generation drugs. Others similarly indicated that although public outcry will continue, people
will pay for value when they see it, and while payers may clamp down on drugs which present
very limited value, it will be at least 10 years before this process catches up to orphan products.
Government payers may increase some restrictions, and EU reimbursement scenarios may in
fact change significantly, as France ponders allowing a maximum of C50,000 per patient per year
and other governments consider standardizing risk-sharing deals, including a revenue claw-back
above a certain threshold, all within the next five years, but the probability of these types of
explicit price controls making it back to the US in a significant way were thought to be very slim.
Finally, healthcare reform's impact on the rare disease space was thought to be negligible as
well, as assisting patients with access to drugs (through removal of the lifetime cap on insurance
payments, etc) was thought to be extraneous in that patients would never be denied a life-
critical treatment, due to the negative public relations outcry such an event would engender,
and as such, patient assistance programs already functioned to provide this same access.
Thus, the overall sentiments from industry and financial analysts are that the broad array of
factors which currently contribute to drug forecasting, as well as those factors which are unique
to orphan drugs, do not currently account for impending changes to legislative,
pharmacoeconomic, or other factors. They contend further that the models are accurate as they
currently stand in that they reflect all current factors relevant to post-approval performance of a
drug, and that any changes to the legislative or reimbursement picture such as those discussed
above were not relevant for inclusion in their respective models given the short time frame
being discussed and the inertia in enacting modifications related to the treatment of orphan
diseases.
Summary of Expert Interviews
Of the 24 expert interviews conducted, 3 claimed to have limited knowledge of the orphan
space and were subsequently excluded from the interview process, leaving 21 qualitative
interviews from which to draw results, or 87.5% of the total.
Within those who were deemed sufficiently knowledgeable in the orphan space, the list includes
nine members from drug companies, servicing a variety of different roles, along with four
commercial payers, two regulatory agents, one legislative representative, three administrative
members of patient groups, one government payer, and three care providers, thus creating a
fairly representative sample for our pilot study, drawn from across the healthcare landscape.
In order to clearly define the results of the expert interviews, we will lay out the conclusions
which will help answer the thesis questions, and subsequently discuss all feedback on a
question-by-question basis from across the full range of experts.
Expert Interview Conclusions
Although individually, many of the experts interviewed presented mixed opinions about the
future of changes to legislative and pharmacoeconomic elements affecting the orphan drug
market, the overarching direction of their thought processes were largely parallel with only one
or two dissentions (discussed below).
The reality which seems likely to emerge in the next five years is fundamentally similar to the
way things have been done in the past, with more significant changes emerging only over the
longer term. Highly innovative and effective drugs will continue to command the price
premiums which they have in the past, but those of more marginal efficacy may increasingly
need to validate their pricing and approval with solid pharmacoeconomic data. Regulatory
conditions for orphan indications will gradually become clearer and may also begin to officially
allow more lenient trials for some orphan products, including the use of historic or dose curve
controls as well as surrogate endpoints with follow-on post-approval studies to help determine
efficacy. Payers, led by those in Washington, will continue to impose restrictions on drug use,
attempt to negotiate as best they can with manufacturers, lead the evolution of risk-sharing
deals in the US, and ultimately pass on a higher burden of the cost to consumers, all while
constructing ever more complex methods of tracking outcomes to better determine clinical
value on their own. However, due to the public relations issues inherent in restricting orphan
drug coverage, the FDA will function as more of a gatekeeper on keeping coverage away from
less effective orphan drugs through its approvals process. Large companies will continue to try
to adapt to the orphan market paradigm with mixed success, and advances in diagnostics will
increasingly impact orphan development and improve outcome measurements. Several new
technologies on the horizon may, in fact, dramatically shift the fundamental mechanisms
affecting the orphan market. Both personalized medicine and gene / stem cell therapies have
the potential to create a mass of orphan indications, which could put so much pressure on costs
as to force a reformation of legislation and / or adjustment of payment schemes. Conversely,
this same change resulting from an increase in "personalized treatment cocktails" might in fact
result in a redefinition of orphan designations along molecular lines, causing several oncology
indications which today are considered orphans to no longer qualify and thus actually shrinking
the pool of orphan indications. Barring a significant paradigm shift, however, the predominant
feeling among most stakeholders is that although orphan indications may no longer be
considered "under the radar" for payers, the options for addressing the cost and reimbursement
issues they present are limited in the short term and will ultimately be overlooked in favor of
lower hanging fruit. When looking at a slightly longer time horizon, several additional changes
may be likely to occur, potentially including government caps on expensive medications, payers
driving PE data requirements to justify pricing, and more effectively negotiated pricing (similar
to what is commonly done today in the EU).
Discussion of Specific Interview Questions
Has the orphan drug legislation been successful in your view? Why or why not?
In this case, almost every expert interviewed agreed with the literature in stating that the
legislation was successful. However, there remained a range among the responses. While Dr.
Tim Cote declared that "there is no question that the Orphan Drug Act is without a doubt the
single most successful piece of legislation that has ever been passed in human experience,"
others were less enthusiastic. What is clear is that the law has done its job to encourage
development for many rare diseases whose patients would otherwise likely be without
treatment today and that in doing so it effectively launched and built the biotech industry into
its current form. Despite these successes, however, some experts also noted that we currently
only have treatments for 200 out of the roughly 7000 rare diseases in existence, and that the
incentives of the Orphan Drug Act only go so far in encouraging for-profit corporations to pursue
treatments for incredibly rare indications. Others similarly noted that the provisions of the ODA
cater more to smaller companies than large ones for a variety of reasons. First, the private
nature of many smaller companies means that they can more legitimately pursue smaller
markets with the hopes of more modest profits without fearing public scrutiny. Additionally,
grants issued by the FDA's Office of Orphan Product Development as well as the waived user fee
for the NDA can make a serious difference to a cash-strapped small business. Finally, the smaller
sales force required to market orphan drugs combined with the explicit marketing exclusivity
clause conveyed with orphan status allows smaller firms to raise capital more easily than for
traditional indications.
Have there been abuses of the system in any way?
The only abuse of the system which came up repeatedly (mostly from patient advocacy groups)
relates to generic drugs which have been subsequently designated for an orphan indication
(such as Colcrys, Makena, and Acthar Gel). While the company inevitably must perform requisite
clinical trials and gain FDA approval, there is little true innovation going on to justify the
prodigious price increases which may then have the effect of limiting access to the drug once
approved. Industry counters this by contending that more physicians will use the drug for its
indication once it has a label, FDA approval, and proper dosing regimens for the orphan
indication, thereby increasing access for patients. Further, these companies will often justify the
price points based on alternative treatment costs. However, many experts argue that this is
fundamentally a marketing innovation and not a research advance, and as such is unfairly taking
advantage of the orphan drug status it was granted. One expert also noted that even assuming
most of the cost of these high-priced drugs is pumped back into R&D for future products /
indications, patients often feel that they are shouldering an unfair burden of treatment for
someone else's disease. That said, most respondents felt that the Act was serving primarily as
intended and that companies were for the most part trying to make use of its incentives to do
good.
What is your opinion on blockbuster drugs which start in the orphan category and expand
from there through multiple indications (orphan or otherwise) or very high pricing? i.e.
Gleevec, Cerezyme, etc?
Most experts who responded to this question claimed that it was unfortunate in some ways for
patients, but ultimately a drug which pursues multiple indications or generally treats a disease
very successfully deserves to earn a significant premium, and this scenario is thus both
warranted and sustainable. As one provider explained, "[Distress over an orphan drug's
expansion to other indications] is like setting up a homeless shelter and one of the members
goes on to become a billionaire." At times it is not even multiple indications which increase a
drug's target population, but simply the fact that it turns a previously fatal disease into a
manageable illness, thereby using the success of the treatment to increase the patient pool, as
many enzyme replacement therapies have done. Several experts claimed that they would
certainly support a claw-back clause to recover taxpayer subsidies for revenues above a certain
threshold or in response to expansion to multiple indications, but they quickly admitted that
since the market will bear the cost of these successful medications and recognize their value,
there is little incentive to change.
How do you think healthcare reform will impact orphan drug pricing? How will it impact
orphan drug incentives overall?
The impact of health reform on orphan drugs seems to depend largely on perspective. The law
itself only contains a few clauses which might impact orphans, namely:
" Removal of a lifetime cap on insurance payments
" Removal of prior condition exclusions
* Allowance for young adults to remain on parents' insurance policies until age 26
" Creation of an Independent Payment Advisory Board (if given real power to target prices,
which remains to be seen)
* Implementation of an excise tax based on market share for brand name sales to Medicare /
Medicaid / DOD / VA; orphan drugs are excluded unless approved for broader indications
" Establishment of Patient Centered Outcomes Research Institute, funded with $650M through
2019 to evaluate efficacy based on outcomes (orphan drugs are excluded for the moment)
Experts here divided largely along stakeholder lines. Industry experts claimed that although the
first three elements should in theory help increase patient access to drugs, in practice most
payers already account for that, and the plethora of industry-sponsored patient assistance
programs means that there are very few cases where patients would not be able to get access
to a medically necessary treatment. From a financial perspective, they pointed out that the law
does very little to change pricing practices for any drugs at all, and certainly for fringe products
such as orphans, "healthcare reform was the only vector to change the way drugs are priced,
and we missed that." Only payers seemed to think that the law's indication that costs will get
squeezed may have broader ramifications in forcing everyone to control pricing, even for rare
and effective products such as many orphan drugs, "in general, all healthcare players will have
to find out how to make do with less."
Do you believe the orphan products space is currently undergoing an increased emphasis on
pharmacoeconomics? How will this impact affect orphan drugs in the short/long term?
One might expect this to be a controversial issue given all the emphasis placed on
pharmacoeconomics in ex-US countries as discussed above. Indeed, some larger plans with
clinical pharmacists on staff are already analyzing disease progression and outcomes data for
non-orphan indications. However, most experts agreed that while PE is certainly helpful in
demonstrating the value of a product and that it may in the next five years play a more central
role in the pricing and access determination of other, traditional drugs, for orphans its use will
remain marginal. Several respondents pointed out that while it sounds terrible to say, from a
strict pharmacoeconomic point of view, the most "valuable" course of action for those patients
with a condition which is expensive to treat is to let them die. Thus, PE studies are by definition
often flawed in the case of orphans and so are rarely used in their simplest sense of
demonstrating a positive cost-benefit; and QALY analysis, everyone agreed, is unlikely to
migrate to the US anytime soon, "price restriction similar to the EU is the perfectly rational thing
to do, but I can imagine the reaction from the tea party and others." Furthermore, orphan drugs
are often restricted to prescriptions from specialists, making payers more comfortable that they
are only being used when necessary. Additionally, there are significant public relations concerns
when considering denying coverage for an indication with unmet medical need. As one expert
dramatically pointed out, "[payer medical directors] never want to go in front of a camera and
say they can't help little Susie because they don't want to pay for it." Other payers pointed out
further that although many drugmakers are now designing trials with the goal of generating PE
data, few payers trust this data enough to base pricing decisions on it; instead some payers are
attempting to create their own outcomes tracking databases, although many expressed doubts
about the usefulness of these databases as well, being that they are targeted toward tracking
patient outcomes and not specifically drug effectiveness.
Will public outcry on drug prices and the determination to pursue cost containment in
healthcare prompt a reexamination of the Orphan Drug Act? How might it change? Do you
feel changes are warranted?
Responses to this question were very clear and differed only mildly across stakeholders. While
published articles will occasionally spark public outcry and even Congressional outrage, the
bottom line is that industry, patient advocacy groups, and physicians concerned primarily with
having more options available for treating patients actually do not want the law to be
reevaluated in any way in the short term. There are still over 6500 diseases for which no
treatment is yet available and patient groups are concerned that any tinkering will cause a
decline in the research aimed at treating those conditions. Indeed, if the proposed amendments
to the law in the early 1990s caused a significant dip in orphan designation requests as discussed
above, there is certainly reason to believe that an angry Congress reworking the law would have
serious adverse effects on industry's willingness to participate in orphan disease research. In
fact, there is pressure from several fronts to increase the incentives offered, whether through
easing regulatory burdens further or by encouraging pharma to open candidate libraries to high
throughput screening by the NIH. Most payers seemed resigned to the law remaining
unchanged (although they certainly were interested in change), but one highlighted the trending
increase in copayments and coinsurance as a way to keep drugmakers honest. They reasoned
that with consumers sharing a larger burden of the cost (whether the end result of this practice
hits the consumer's pocket is still unclear) there will be a drive for transparency in pricing which
will not allow egregious price increases to go unnoticed, initiating a "day of reckoning" for actual
drug value.
Do you think the FDA is employing a greater import on safety currently? Will the FDA amend
the safety constraints for orphan products (whether more tight or lax)?
Only a few experts felt they were in a position to comment on this point, but the overarching
feeling seemed to be that standards for acceptance of orphan trials were still not very clear, and
that the agency must do a better job of clarifying the regulatory pathway for orphan products. In
that vein, the FDA established a "Rare Disease" unit within the Office of New Drugs in 2010 to
help facilitate approval for orphan treatments. However, for the time being, there is still a
significant gap between looking at what the FDA has accepted historically as evidence for
approval and being certain of what will be considered sufficient in the future, especially as
traditional drugs face increasingly tough standards for obtaining approval. The FDA would
generally prefer to see placebo-controlled trials with enough patients to demonstrate statistical
significance and a valid safety profile. While the safety profile issue may be relaxed in orphan
indications, running a placebo-controlled trial when another treatment exists is often unethical,
and finding enough patients to demonstrate significance can be time consuming or even
impossible. Patient groups and providers align closely with industry on this point, as their
primary goals are to enable more treatments for more diseases more quickly. That said, since
orphans typically have high mortality rates and a large unmet need, it has historically been fairly
easy to convince the FDA of clinical benefit. Many ERT studies have sufficed with using either
historic or dose-curve controls and no placebo. Surrogate endpoints are not currently commonly
used, but have been allowed in specific circumstances (Avastin, for example, was approved
based on a surrogate endpoint). Yet respondents suggested that surrogate endpoints combined
with post-approval studies of outcomes to determine efficacy may be crucial policy in approving
orphan products in the future in order to compensate for the small number of patients and long
time horizons or ethical considerations that using an endpoint of mortality would suggest.
Unfortunately, due to the difficulty of running trials once a drug has been approved, the FDA
often does not believe it will ever be privy to the post-approval trial results and so is still
reluctant to create a standard guidance based on this regulatory pathway.
Do you believe big pharma will continue to pursue orphan indications? What impact will
having more players in the orphan space have on the public view of orphan incentives?
There is little question that large pharmaceutical companies have made it clear externally that
they would like to take a bigger role in the rare disease space. What is not entirely clear,
however, is how they intend to pursue this goal or whether they are in fact adequately prepared
to succeed in this market. For all the media hype, several industry insiders pointed out
skeptically that most pharma companies have not created new units to specifically perform R&D
on new orphan drug candidates. Rather, they have primarily been engaged in a strategy to scour
the late-stage pipelines of smaller companies and attempt to pick off the winners. This is not so
much an effective way to help create innovation for unmet medical need as it is a way to restock
a depleted pipeline. Further, many experts feel that with large sales forces dominating the
pharma landscape, the emphasis in rare diseases on individual patients means that orphans will
never succeed as a large part of the business model. As one prominent patient advocacy group
leader unequivocally stated, "big companies don't understand the business model which is very
unique and very different." Indeed, several smaller companies have sprung up to try to perform
patient services for big pharma companies unprepared or unwilling to do this work for
themselves (one example is Centric Health Resources). Additionally, payers may expect to see
lower prices from companies with deep pockets and pricing practices may therefore be volatile
from a public relations perspective (although somewhat offset by the positive PR from
addressing an unmet need). Finally, often corporate integrity agreements at large pharma
companies prevent them from engaging directly with patients in the way that biotech
companies do as part of standard business practices. Thus, the overall perspective was that
most stakeholders are unimpressed with big pharma's claim of jumping into orphan drugs
(although it is a bit more difficult to argue with Sanofi-Aventis' purchase of Genzyme for over
$20Bn), and most do not believe it is a sustainable new market for them as currently structured.
That said, payers were obviously not thrilled with the prospect, but believed that unless the
number of approved orphan products jumped 10-fold in the next few years, they would keep
covering drugs in the orphan space even coming from larger companies, as the negative PR
earned from denying coverage remains a poor tradeoff. Additionally, the consensus was that for
big pharma to get into orphan diseases in a truly meaningful way would require spinning off a
separate company to perform real R&D on prospective candidates with more of a biotech
business model attached to it, encompassing intimate patient support and appropriate
marketing services.
Do you think there are any key differences in the market today over in the past (i.e. if Gleevec
or Cerezyme were launching today, what would be done differently and how might that
impact profitability)?
Again emphasizing that in the short-term the orphan industry will largely remain the same,
experts asserted that in cases of clear value such as Gleevec or ERTs such as Cerezyme, high
prices would be expected and tolerated. Cerezyme has demonstrated the ability for a drug to
increase its patient population by virtue of creating a manageable illness out of a fatal disease,
but while it is possible that regulators and payers will start looking at the potential for new
indications when considering orphan drugs, on the whole such a development is unlikely. What
does tend to rile payers are when pills are priced like biologics in treating the same illness (since
the margins are significantly higher), as well as any effort to significantly raise prices after launch
or to introduce different prices for a change in dose. The latter was attempted recently by
Genentech, as it was discovered that Lucentis, a treatment for wet macular degeneration, was
very similar to Avastin, but required a much smaller dose (thereby eliciting a much lower price).
In order to keep prices up, Genentech claimed that they were in fact different molecules, but
the NIH elected to undertake a trial to show that they are functionally equivalent, allowing
physicians to simply use a small amount of Avastin to treat patients with WMD. Additionally,
when looking at orphan drugs which are slightly less effective than blockbusters such as Gleevec
or Cerezyme (such as many of the newer cancer medications) as well as ultra-orphan
indications, there may in fact be different market factors in play nowadays, as it is harder for
small firms to find funding for such drugs, and the regulatory pathway as discussed above is
extremely murky. One element which may be changing (again, primarily for less effective
treatments or drugs targeting much smaller patient populations) is the incidence of risk sharing
deals where the pharmaceutical maker agrees to shoulder some of the risk for treatment
efficacy. This initiative seems to be slowly gaining steam, especially in the EU, and many experts
thought this was something which may take hold back in the US as well.
What other changes in the next five years do you see affecting the orphan market, from the
perspective of pricing, reimbursement, regulation, incentives, or costs? How about longer
term?
Many important trends were identified as likely to either increase or continue, but none would
qualify as a large-scale change in orphan market factors which might significantly impact current
forecasting models, although it may potentially be more difficult to get approval of drugs which
are only marginally innovative or efficacious. The short-term changes highlighted, with
stakeholder identification, were:
" Big pharma may become more conservative and lose interest in orphan indications (provider /
industry)
" FDA regulatory process will become clearer (industry / patient group)
" Share of costs shouldered by patients will continue to increase, even up to 20% (payer /
patient group)
" Payers may continue to impose restrictions on orphan drug access through formulary tiers, etc
(patient group)
" FDA will function as the primary gatekeeper for orphan drug coverage, as once approved,
most drugs will continue to receive coverage (industry)
" Rare disease research (especially for ultra-rare diseases) will become more heavily dependent
on charities / patient groups over industry (provider)
* Better risk pooling for people with chronic illnesses, potentially even government stepping in
to pay for those patients (payer)
" More harmonization with international designation process, no major regulatory changes
(regulatory)
" Biologics slowly replaced by orals, but this will not lower prices much for orphans (industry)
e Marginally efficacious drugs will have a harder time commanding the same reimbursement
rates as more innovative ones (government payer / industry)
* More price negotiations with manufacturers by both government and commercial payers
(government payer/ industry)
" Government payers, as they become stressed to deal with costs, will require "coverage with
evidence" (a form of forced outcomes research) and will use the national coverage process to
help deal with costs (government payer/ industry)
" As physicians affiliate more with managed care and hospitals and band together, they will
increasingly have power to negotiate with manufacturers over prices as well (industry)
e Payers will begin tracking outcomes more effectively in an effort to generate their own
efficacy data (industry)
* Diagnostics will play an increasingly large role in helping drugmakers to demonstrate the value
and effectiveness of their products (industry)
" With growing pressure for access to new treatments, surrogate endpoints combined with
post-approval efficacy studies will become more accepted in the orphan space (industry)
* More of the same (industry / payer / patient group / regulatory)
Several stakeholders did mention that looking at a slightly longer time horizon, several
additional changes may be likely to occur, potentially including government caps on expensive
medications, payers driving PE data requirements to justify pricing, and more negotiated pricing
(similar to what is commonly done in the EU). Additionally, as mentioned above, several
technological developments such as the emergence of gene and stem cell therapies,
personalized medicine, and molecular diagnostics may necessitate a reworking of the orphan
drug legislation to more narrowly define products which are eligible for orphan incentives.
It is also important to note that there were two dissentions from among the responders, one of
whom articulated that due to mounting budget constraints, pricing is coming under pressure in
both the EU and the US, with the implication that it is very possible that in the next five years
data will be required to show the value of treatment in both geographies and orphan pricing will
come back to earth as more payers recognize their growing overall burden. The other dissenter
was more moderate, and made it clear that we are currently in a state of flux, "we are
witnessing a culmination of two very different political philosophies or ideologies around this,
and the politics are not necessarily functioning at the moment to work it out, but we are seeing
unprecedented pressures toward cost containment; and at the same time we are looking at a
fear of rationing, sometimes from the same people." That said, "I do know that the days of drug
companies and specialists writing blank checks on these drugs is over-there will be much more
scrutiny on the value of these drugs and what does clinical value mean." Most experts, however,
did not agree, as one payer resignedly pointed out, "a $1M pill is likely to launch in the next two
years and our hands are tied in US."
Thus, the reality which seems likely to emerge in the next five years is something of a
compromise. Highly innovative and effective drugs will continue to command the price
premiums which they have in the past, but those of more marginal efficacy will need to validate
their pricing and approval with solid PE data. Regulatory conditions for orphan indications will
gradually become clearer (and possibly more lenient), and payers, led by those in Washington,
will continue to impose restrictions on drug use, attempt to negotiate as best they can with
manufacturers, evolve further risk-sharing deals, and ultimately pass on a higher burden of the
cost to consumers, all while constructing ever more complex methods of tracking outcomes to
better determine clinical value on their own. Still, due to public relations issues with restricting
orphan drug coverage, the FDA will function as more of a gatekeeper on keeping coverage away
from less effective orphan drugs through its approvals process. New technologies, including
gene and stem cell therapies, personalized medicine, and diagnostics will increasingly impact
orphan definitions and development, and large companies will continue to try to adapt to the
orphan market paradigm with mixed success.
Chapter 5: Discussion
Through this limited pilot study, we examined the potential of several trends within the
prescription drug landscape to significantly alter the value proposition of orphan drugs in the
short term future. Although the net effects of these changes would be wide-ranging, we elected
to use forecasting models employed by the finance and pharmaceutical industries as a tangible
example of those directly impacted by our results. As such, we interviewed analysts from both
industries to obtain a baseline from which to assess changes in the short-term future of the
orphan drug space. A five year time frame was selected as the most reasonable in that it
balances the slow speed of enacting meaningful changes (whether legislative or otherwise) with
the ability of industry stakeholders to make educated predictions about emerging trends and
paradigm shifts.
We subsequently focused on attaining a broad picture of the concerns of stakeholders from a
wide-range of healthcare functions, including various functions within industry, patient groups,
providers, legislators, regulators, and industry consultants, and we deliberately asked open-
ended questions in the hope of arriving at meaningful qualitative conclusions. In order to form
the basis for the interview questions and to have a strong background from which to discuss
interviewee opinions, an extensive literature review was conducted to better understand
several influential elements: the history of orphan drug legislation both in the US and elsewhere,
public and industry concerns over current pricing, access, and reimbursement mechanisms,
specific company profiles, and current trends as reflected in journal articles and the media over
recent months.
Our hypothesis that existing forecasting models will fail given impending changes to influential
market factors in the orphan drug space was not supported, as it would appear that at least
over such a short time horizon, most variables currently employed in orphan drug models will
continue to be relevant as before. However, two important factors came to light which qualify
this result. First, when considering a slightly longer time horizon many experts did, in fact,
expect significant changes to the orphan drug reimbursement paradigm, whether due to
legislative, regulatory, or technological shifts, as pressures on costs driven by payers, patients,
and physicians continue to mount. Furthermore, drugs which display marginal efficacy (and the
definitions for marginal efficacy will likely become more clear as well) may indeed face the need
to justify their pricing in the next five years, and may in fact be subject to significant restrictions
and lower prices than their wildly innovative and effective orphan counterparts. This difference
should indeed be reflected in forecasting models, though to say that they willfail if used in their
current state based on this subset of drugs is unfair. This prospective change is also subject to
the caveat that so long as patients clamor eagerly for the newest medications, and so long as
political figures follow their lead, even less-effective drugs may yet continue to command high
prices despite the outrage this may generate, as public relations issues continue to dominate
more rational payer policies, leaving only CMS to lead the way in addressing high prices.
Implications
While the hypothesis was not supported, our results have significant implications for analysts as
well as those either currently operating in or preparing to enter the orphan drug market.
Understanding stakeholder biases and motivations can significantly help mitigate the effects of
unexpected change, and as several technologies have the potential to capriciously amend the
definition and treatment of orphan drugs, it is imperative that companies active in this space
keep a close eye on the progression of those fields. Long range planning guidance should
consider the changes likely to take place after the five year mark as well, and, as we have
shown, such changes have the potential to be very significant in their own right.
The implications from these results also resonate on an individual level for stakeholders.
Regulators should understand the confusion around the orphan drug pathway and seek to
clarify details around surrogate endpoints and studies with non-placebo controls. Payers should
continue to be mindful of the threat orphan drugs present to their cost structure and must
become leaders of innovation in managing these products, whether that includes designing and
implementing research-oriented databases to understand drug efficacy, working to implement
new risk-sharing deals, or pressuring government payers to take the politically difficult lead on
tackling drug prices. Patient groups and physicians must be aware of the funding shortage likely
evolving for ultra-orphan indications, and need to temper their enthusiasm for new treatments
with an understanding of the benefits of keeping healthcare costs down. If forgoing approval of
a therapy which extends life for one month in a cancer patient means that there will be funds
for creating a cure for a disease affecting 1000 people worldwide, that ethical conundrum will
likely be partially decided indirectly by their efforts. Similarly, pressing for less-effective new
treatments to be reimbursed means that a growing share of drug payments will continue to be
borne by patients, which may ultimately lead to decreased access on a much broader scale.
Legislators, by virtue of their political agenda, will always play to public sympathies, and while
the Orphan Drug Act may be largely safe from tampering, transparency has its benefits as well,
and pushing for cost containment in intelligent ways which the public can rally behind could
provide a change the field desperately needs. Pharmaceutical and biotech companies will need
to adjust in the coming years to the new reality that less effective drugs will likely be subject to
lower prices and higher data requirements, whether this reality is enforced by payers or by the
FDA. While this certainly adds some risk to all drug development and even greater risk to orphan
drug development, it remains an area where drugmakers can take the lead as well in creating
innovative solutions. Improvement of the science of generating standardized
pharmacoeconomic data through trials will allow payers to trust more in the resultant care
offered to the patient. Risk-sharing deals, which are already growing in popularity in the EU, are
likewise a very effective way to convince a doubtful public and payer community that a drug is
truly delivering the value it commands as payment.
Limitations
The selection of both analysts and expert interviewees was intended to provide a wide view of
ongoing trends in the orphan drug space and to enable this study to serve as a roadmap for
future research, not necessarily to reach statistically significant conclusions. Time constraints
and the difficulty of contacting some individuals limited the experience level of several of the
respondents, and our attempt to reach a wider array of experts left fewer individuals
representing each specific stakeholder position. Additionally, the diversity of experts contacted
represents a large segment of the healthcare landscape, but is by no means a fully
representative sampling. For example, our legislative contact was limited to one Congressional
staffer, and several attempts to contact Massachusetts state public health institutions were
rebuffed. Similarly, we could have extended interviews to those running patient assistance
programs, hospital formulary managers, pharmacy benefit managers, etc.
Another limitation is that our pilot study is very focused on those in the Massachusetts area, and
this geographic bias can potentially have an impact on our results as well. Various payers across
the nation are endeavoring to deal with cost issues in different and creative ways, and our focus
on the Northeast has limited our exposure to those ideas. Several individuals interviewed
neglected to comment on one or more of the questions, for fear of being quoted out of context
on areas which were not directly related to their official capacity, or for fear of having their
ideas assigned back to their respective institutions. Due to the methods for recruiting individuals
for interviews, there is a possibility of selection bias as well, as apart from those within industry,
many of the experts have direct academic ties, which might potentially cause them to share a
unified view of emerging trends in the drug industry.
There is clear variability among the experts interviewed relating to their familiarity with either
orphan drug legislation or specific trends within the healthcare landscape. Many refused to
answer questions with whose subject they were only passingly familiar, and still others
tempered their claims by stating unequivocally that they were only speculating on specific
issues. In all cases, these remarks have been lent lesser weight in our results, but they still
represent one limitation of presenting a wide-ranging questionnaire uniformly to a diverse
group of people.
Future Research
Our discussion with stakeholders from across the healthcare landscape has significant
implications for future research and may serve as a roadmap for follow-up studies with greater
resources. While many of the projected changes do not seem poised to affect the orphan drug
market in the short term, longer term implications clearly have the potential to significantly
alter forecasting and revenues in the orphan drug space.
Repeating this study five years from now, for example, would be a fascinating commentary on
the pace of change in the healthcare industry, and would yield a better understanding of what
factors, if any, have the capability to quantifiably impact orphan drug pricing and
reimbursement in a rapid way. The study could further be extended to include many additional
stakeholders in the healthcare space to attain an even broader view of prospective changes, and
could also be amended to provide a retrospective analysis of changes occurring between today
and such a future date, eliciting an understanding of common biases shared by those involved in
the healthcare space.
Further studies may also choose to assess a larger array of impacted areas; for example,
understanding how employment opportunities may change based on paradigm shifts in orphan
drugs, or assessing where the balance of power may be found among different stakeholders at
various times in history and how such a power shift might further impact commercial and public
strategies going forward. Our results could also serve as a basis for more quantitative work,
examining actual drug revenues as compared to analyst predictions over time to understand
which market factor changes led most frequently to inaccuracies, with the goal once again to
devise strategies which may be undertaken to effectively mitigate these situations.
Future work may also be conducted by specific stakeholders with potentially interesting results,
as a study of a similar nature undertaken by the FDA, for example, might motivate a
reassessment of some of the uncertain regulatory issues surrounding orphan drug policy or may
lead to more creative solutions to some of the problems encountered based on the specific
influence available to those performing the study.
Chapter 6: Additional Challenges
The results obtained from the literature review as well as the stakeholder interviews highlight
the very real challenges involved in the process of creating pricing, reimbursement, and access
standards for orphan products which allow for a fair sharing of value among all involved parties.
These challenges are greatly exacerbated by the fact that while making people better is simply a
business to some, it is a matter of life and death to others, and emotions tend to rule the day.
Thus, the sensitivity of applying any form of economic analysis to the ethical and highly personal
issues which permeate the orphan product space must be carefully considered from multiple
distinct perspectives in order to effectively view the entire picture. That said, while drug
revenue models may not be changing dramatically in the next five years, it is worth examining in
detail some of the more impactful trends which may be emerging to attempt to devise effective
and progressive mitigation strategies for dealing with them.
Generics Marketed as Orphan Products
One of the trends which has never failed to elicit a strong and emotional response from payers,
politicians, patient groups, and the general public is the practice discussed above wherein
drugmakers run trials and receive approval for an orphan indication based on a molecule which
is already available as a generic, and which may already even be fairly widely used for the same
indication. As one payer succinctly put it, "rehabilitated drugs drive up healthcare costs under
the guise of cost-effectiveness." In a recent article in the New England Journal of Medicine,
several physicians argue the case against Colchisine (brand name Colcrys), a drug approved for
acute treatment of gouty arthritis, whose ancestral plant was already being used to treat gout as
early as 3000 years ago, and whose tablet form was widely available as a generic in the US since
the 1 9 th century. The manufacturer, URL Pharma, further applied for and received seven year
exclusivity for the orphan indication of familial Mediterranean fever based on a review of
previously collected data and pharmacokinetic trials. As the price subsequently jumped over
50x, the authors argue that patient access was thereby restricted, and funds were diverted from
other worthwhile healthcare causes to pay for the newly branded medication. This case
therefore reveals a flaw in orphan drug incentives which negatively impacts the overall
healthcare market23 .While it is difficult to argue with the case that some rebranded generics
represent a failure of orphan incentives, drawing a clear line is not nearly as simple as
disallowing the application of incentives to non-innovative products. How does one determine
the actual added value of FDA approval and correct dosing? How many new trials need to be run
to justify a given price increase by a manufacturer? With arguments in each direction, can
anyone actually quantify the change (positive or negative) in patient access to a drug once it
attains FDA approval? These questions must be answered in an evidence-based approach before
drastic action may safely be taken. Were the NIH to sponsor trials for drugs which are known to
be effective for a given condition in order to preempt a drug company doing so for profit,
everyone might benefit at a fraction of the cost, yet until this concept catches on, drugs such as
Colcrys and Makena will continue to rile the media and give the orphan drug system a bad
name.
Government Recommendations
Between 2008 and 2010 both the US and EU commissioned reports for recommendations in
helping to advance the cause of rare diseases. The US report, which was jointly conducted by
the FDA, the NIH, and the Institute of Medicine, examined the challenges in attracting public
and commercial funding for R&D, obtaining sufficient numbers of research participants,
designing sound clinical trials, and truly assessing safety and efficacy prior to marketing
approval20 .A similar study was put out by the European Commission in 2008, and the results of
this second study present a good indication of how the EU is encouraging stakeholders to tackle
several of the major challenges facing the orphan product space. First, the report emphasizes
the importance of establishing early dialogue between companies and pricing / reimbursement
authorities to discuss clinical data needed for later clinical value assessments, thus providing the
company with more certainty around the process and the authorities with more trust in the trial
results. Second, the report requests greater knowledge exchange between member states on
the added clinical value of specific drugs. Third, it encourages initial uptake through conditional
pricing and reimbursement decisions, thus allowing faster access to patients while controlling
utilization, budgets, review timing, and further studies. Finally, the report encourages building
EU-level expertise in rare diseases, creating EU-wide patient registries and networks of centers
of expertise, and assistance with supply issues as well as post-approval studies8. These
suggestions are equally applicable to the US in combination with the EU, as encouraging better
use of global patient registries, more open dialogue with regulators and reimbursement
agencies, knowledge exchange (both clinically and from a value perspective), and more wide-
spread implementation of risk-sharing strategies are concepts that are universally necessary and
would benefit the widest spectrum of stakeholders.
Risk-Sharing Agreements
One concept which is gaining steam much more quickly outside the US, but which will likely
migrate towards the US as well, is the emergence of risk sharing deals between payers and
industry. One of the most widely publicized such deals involved Velcade treatment in the UK in
2007, wherein Millenium agreed to reduce the price paid for the drug if the health outcomes of
those using it initially did not indicate a predetermined level of efficacy. Roche followed suit,
inking a deal with NICE for rebates on Tarceva , as did Merck-Serono for Erbitux as well. Other
agreements, such as the one between Novartis and the NHS over Lucentis in 2008, differed
slightly in that the manufacturer agreed to pay for any treatments required beyond an initial
number. An early risk sharing scheme for treating multiple sclerosis in the UK involved a
maximum price per QALY for Avonex, Betaferon, Rebif, and Copaxone. GSK created a deal in
which they offered a 12.5% price cut and a rebate if their drug failed a head-to-head trial against
a comparable drug from Pfizer. Such agreements are gradually pushing their way into the US
markets as well, although not currently at a national level. Merck and Cigna have a risk sharing
agreement over diabetes drugs, and United Healthcare and Genomic health recently enacted a
temporary agreement over a breast cancer diagnostic testa
Figure 6: Select risk sharing deals in biotech / pharma
Sponsor DrugCounterparty YearDeas
Multiple MS drugs -Avonex, UK 2002 Maximum price I QALY of
Betaferon, Rebif, E36,000
Copaxone
Novartis Diovan US 2004 Patient money-back guarantee
Bayer Levitra Denmark 2005 Refunded cost to unsatisfied
patients
J&J Velcade UK 2007 Reimbursement to healthcare
system if tumors did not shrink
Novartis Lucentis UK 2008 Pay for all treatments required
beyond initial 14
Merck Janumet / Januvia Cigna 2009 Discounts to drug prices when
successful and compliance
GSK Votrient UK 2010 12.5% price cut + rebate if fail
H2H vs Pfizer's Sutent
Recent Trends: Drug sponsor to pay for specific adverse events while patient on therapy
e.g. SA/P&G deal with Health Alliance to pay for fracture costs for patients on Actonel,
Cigna asking drug makers of cholesterol-lowering pills to pay for myocardial infarctions
While these deals provide a potentially valuable way to reduce risk and improve patient
outcomes in the future, and may be especially valuable in orphan indications, criticisms abound.
For one thing, there is little current evidence that these deals actually result in significant
savings for payers. Further, most of the risk-sharing agreements came about due to a coverage
or reimbursement rejection of a drug, and consequently there has been little or no
standardization among manufacturers or payers on deal parameters, measures of effectiveness,
or implementation4 . In the US, moreover, although CMS has the ability to require "coverage
with evidence", at the moment deals are only struck with individual commercial payers. Going
forward, this practice needs to become more widely accepted, especially in the orphan space,
where initial trials are necessarily difficult. As indicated above, payers do not balk at paying for
valuable treatments which significantly help patients, but proving such effect remains a
significant hurdle in many cases. Standardization of risk-sharing processes and outcome
measurements can go a long way toward controlling costs and helping to more adequately
share value in the healthcare system.
Global Impact
Another challenge facing the orphan market in coming years is the emergence of developing
countries onto the global landscape. Current reimbursement procedures are such that it only
makes sense to charge for an orphan drug in industrialized countries with advanced payer
systems. Often, drug manufacturers find (in non-orphan indications as well) that charging a
significantly lower price in a developing country for the same drug can cause a public relations
nightmare which is not nearly offset by the added revenue, as US patients argue that they are
subsidizing the global pharmaceutical market. This presents a problem for patient-focused
companies, as a commitment to leaving no patients without care means that they must then
offer many of their treatments for free, while simultaneously pleading with the government to
offer full reimbursement. Potentially a deal wherein western NGOs fund drugs for a small
percentage of the full price for a group of patients in developing countries would be more
palatable than simply discounting the price outright. How these negotiations evolve will play an
ever-growing role in the ability of orphan drug manufacturers to command high prices.
Chapter 7: Conclusions
Our results highlight the fact that thought leaders from across the healthcare landscape
predominantly do not feel that large scale change will impact the orphan market over the next
five years, and certainly not in such a way as to require a significant change to currently
employed orphan drug forecasting models. Indeed, it seems fair to conclude that the perceived
value proposition of orphan products is unchanging in the near future, as the perspectives of
current opinion leaders do not suggest changes to the commercial or political value inherent in
such products anytime soon. Even without such dire changes, however, our research has
implications for each set of stakeholders in the orphan product space to reexamine
unsustainable practices and to take initiative in creating innovation and implementing solutions
to some of the serious economic challenges affecting the industry, whether problematic
currently or in ten years time. As budgets are constrained across the board, some of this
innovation is already occurring elsewhere in healthcare. The Blue Cross Blue Shield Alternative
Quality Contract is effectively a more palatable form of capitation and seeks to supplant the fee-
for-service model so common in medicine. Physicians are beginning to band together to demand
equal discounting for drugs and supplies much like the discounts commonly provided to larger
purchasing organizations. Nonprofit organizations, such as the National Quality Forum, are
seeking to bring many different stakeholders together to help build consensus on devising
national priorities and goals for performance improvement, creating quality measurement
systems, improving public performance reporting, and promoting education and outreach
programs. Large segments of the healthcare community are thus already recognizing the need
for concrete action and leadership, and our results demonstrate that many of those within the
orphan community must recognize that there are challenges to be addressed in this space as
well.
Challengesfor Regulators and Legislators
1. Understand the confusion around the orphan drug pathway and seek to clarify details
relating to surrogate endpoints and studies with non-placebo controls.
2. Work with the pharmaceutical industry to create a framework for post-approval studies
which will enable patient access to crucial medications more quickly.
3. Pay close attention to emerging technologies such as stem cell and gene therapies and
personalized medicine to understand their potentially unintended impact on orphan
incentives and costs.
4. Concentrate on easing existing challenges in the orphan space through increased focus on
global collaboration for orphan designation and approval, as well as global patient registries.
5. Standardize control of orphan drug incentive misuse, either through direct
legislative/regulatory changes, or through government sponsored trials of the generic drugs
often used for off-label treatment.
6. Allow CMS more power in negotiating pricing decisions, in balance with continuing to
adequately incentivize industry to deliver innovative medical treatments.
7. Strive for transparency in discussing issues with orphan drug pricing from both an emotional
and an economic perspective, always involving multiple stakeholders in discussions.
Challenges for Payers
1. Take a more active role in understanding actual medical impact of orphan drugs through
improved outcomes and research focused databases, despite the limited budgetary impact
these diseases currently represent.
2. Begin to standardize and insist more widely on risk-sharing deals and their accompanying
outcome measures, to help offset costs in a politically acceptable way.
3. Endeavor to better understand how increases in copayments and coinsurance rates impact
access to orphan drugs and understand the indirect consequences of attempting to shift
costs in this way.
4. Collaborate with industry to determine (for all drugs) which pharmacoeconomic factors are
valuable in assessing drug performance, and assist with designing trials and databases to
meet those goals.
Challenges for Patients, Patient Advocacy Groups, and Providers
1. Understand the impact of impending funding shortages for research in ultra-orphan
indications and pursue alternative methods for designing treatments for these diseases,
such as incentivizing pharmaceutical companies to open up massive candidate libraries to
the NIH for high throughput screening.
2. Strike a balance between pushing for new treatments to emerge as quickly as possible, even
with marginal efficacy, and the indirect costs which such speed may have on funding for
other diseases.
3. Work with payers and industry to determine what steps may be taken to reduce the
growing cost burden on patients, and understand quantitatively how that increasing burden
is impacting patients' access to drugs.
Challengesfor Industry
1. Adjust to the impending reality that less effective drugs may be rejected or covered at a
lower cost, but will inevitably require better data validation for pricing.
2. Work with payers, both commercial and government, to help create trustworthy
pharmacoeconomic assessments, and thereby help justify pricing in the eyes of payers as
well an increasingly skeptical public.
3. Engage the orphan market globally, helping to treat patients outside of developed countries
in a way which earns revenue while minimizing public relations damage, thus helping to
offset cost pressures in the US.
4. Lead the way by standardizing risk-sharing deals with US payers and proactively offering
such deals (not simply post-rejection) as proof of value added.
Appendix A: Interview Contacts
e Andrew Curtis, Strategy / Innovations for Biotherapeutics (formerly head of Rare Disease Unit),
Pfizer
e Andrew Tager, M.D., Mass General Hospital
* Bill Kassler, Chief Medical Officer- New England Region, CMS
* Bill McColl, Political Director, AIDS Action
e Catherine Courtin, Launch Brands, Biogen Idec
* Chris Hren, Global Hemophilia Marketing, Biogen Idec
* David Caponera, Access Services, Pfizer
* David Gilman, Partner, The Frankel Group
e David Miller, Market Access, Biogen Idec
* Dee Simons, Government Reimbursement Policy, Biogen Idec
* Diane Dorman, VP of Public Policy, National Organization for Rare Diseases
* Diego Sanchez, Legislative Assistant to Congressman Barney Frank
* Edwin Choy, M.D., Mass General Hospital
* Elkan Gamzu, former CEO, Cambridge Neuroscience
* Gayle Silverman, Portfolio Maximization, Pfizer
* Howard Moy, Direct Market Access, Pfizer
e Jan Cook, Medical Director- Medical Innovation and Leadership, Blue Cross Blue Shield of
Massachusetts
e Jeff Fritch, Regulatory Review Officer, FDA Office of Orphan Product Development
e Jim Coccia, Commercial Decision Support, Genzyme
* Jim Hancovsky, VP Pharmacy, United Healthcare
e Jonathan Gertler, Partner, Back Bay Life Science Advisors
* Julie Kerner, New Product Commercialization, Biogen Idec
* Mara Aspinall, CEO On-Q-ity (formerly president of Genzyme Genetics)
e Matt Trudeau, Global Marketing, Biogen Idec
e Michael Schmidt, Analyst, Leerink Swann
" Mike Poirier, Regulatory Affairs, Biogen Idec
* Rob Brekosky, Pharmacy Program Operations Director, United Healthcare
e Susan Maddux, National Director, United Healthcare
e Tim Cote, Director Orphan Products, FDA
e Vikas Sukhatme, Chief Academic Officer, Beth Israel Deaconess
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Additional Notes
A. Mark Merritt, chief executive of the Pharmaceutical Care Management Organization
explained that use of these "pay-cards" by industry is short-sighted since plans will
inevitably find ways to limit their use.
B. This question was deliberately phrased in a harsh light in order to evoke significantly
divergent responses from the various stakeholders interviewed.
